Development setbacks overshadow Basilea's reduced net loss
This article was originally published in Scrip
Executive Summary
Basilea has confirmed that the US Phase III study of its oral treatment for severe chronic hand eczema, Toctino (alitretinoin), is delayed by 12 months. The results are now due at the end of 2011, with a filing expected for 2012, the company said while reporting its half-year financial results that showed a reduced net loss for the company in the first half.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.